MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 255-260

  Wang, Yong Sheng ^a   Wang, Yin Hua ^b   Xia, Hong Ping ^c   Zhou, Song Wen ^a   Schmid Bindert, Gerald ^d   Zhou, Cai Cun ^a  

^a TONGJI UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acquired resistance; Gefitinib; MiR 214; PTEN; Signaling pathway

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MICRORNA; MIRN214 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84864865233     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.255     Document Type: Article

References (39)

1. Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
2. Bean J, Brennan C, Shih JY, et al (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA, 104, 20932-7.
3. Blower PE, Chung JH, Verducci JS, et al. (2008). MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther, 7, 1-9.
4. Derfoul, A, Juan AH, Difilippantonio MJ, et al (2011). Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis, 32, 1607-14.
5. Engelman JA, Mukohara T, Zejnullahu K, et al (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest, 116, 2695-706.
6. Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.
7. Esquela-Kerscher A, Slack FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69.
8. Fu YF, Du TT, Dong M, et al (2009). Mir-144 selectively regulates embryonic a-hemoglobin synthesis during primitive erythropoiesis. Blood, 113, 1340-9.
9. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
10. He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31.
11. Hu SJ, Ren G, Liu JL, et al (2008). MicroRNA expression and regulation in mouse uterus during embryo implantation. J Biol Chem, 283, 23473-84.
12. Hwang HW, Mendell JT (2006). MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer, 94, 776-80.
13. Jackman D, Pao W, Riely GJ, et al (2010). Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol, 28, 357-60.
14. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
15. Kosaka T, Yatabe Y, Endoh H, et al (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 12, 5764-9.
16. Lee KM, Choi EJ, Kim IA (2011). microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol, 101, 171-6.
17. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
18. Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
19. Magrelli A, Azzalin G, Salvatore M, et al (2009). Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol, 2, 157-63.
20. Mellinghoff IK, Cloughesy TF, Mischel PS (2007). PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res, 13, 378-81.
21. Mendelsohn J, Baselga J (2000). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-65.
22. Miller TE, Ghoshal K, Ramaswamy B, et al (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem, 283, 29897-903.
23. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
24. Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73.
25. Pillai RS (2005). MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 11, 1753-61.
26. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hemat, 19, 183-232.
27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.
28. Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61.
29. Sulis ML, Parsons R (2003). PTEN: from pathology to biology. Trends Cell Biol 13, 478-83.
30. Tamura M, Gu J, Matsumoto K, et al (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-7.
31. Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37.
32. Weiss GJ, Bemis LT, Nakajima E, et al (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol, 19, 1053-9.
33. Xia L, Zhang D, Du R, et al (2008). miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 123, 372-9.
34. Yamasaki F, Johansen MJ, Zhang D, et al (2007). Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res, 67, 5779-88.
35. Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98.
36. Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33.
37. Yang Z, Chen S, Luan X, et al (2009). MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life, 61, 1075-82.
38. Zhang XJ, Ye H, Zeng CW, et al (2010). Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol, 3, 46.
39. Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 12, 735-42.